Given the interest in harnessing UCP1 activity in BAT for treatment of metabolic diseases (Chondronikola et al, 2014; Nedergaard et al, 2007; Saito et al, 2009; Cypess et al, 2009), our study completes our understanding of UCP1 inhibition by naturally occurring nucleotides. The gene discussed is UCP1; the disease is metabolic disease.